Neuroscientific Biopharmaceuticals Ltd. (AU:NSB)
ASX:NSB
Top Page
Neuroscientific Biopharmaceuticals Ltd.
(Sydney:NSB)
Select Model
Select Model
Rating:46Neutral
Price Target:
AU$0.10
▼(-3.00% Downside)
Action:ReiteratedDate:04/02/26
The score is primarily held down by weak financial performance (revenue collapse, continued losses, and cash burn), partially offset by a debt-free balance sheet. Technicals are mixed with short-term improvement but a broader downtrend, and valuation is constrained by a negative P/E and no dividend support.
Positive Factors
Debt-free balance sheet
A reported zero-debt position materially reduces solvency and interest-service risk over the medium term. That structural flexibility lets the company prioritize R&D and clinical timelines without mandatory fixed debt payments, improving survival odds through multi-year biotech cycles.
Negative Factors
Revenue collapsed to zero (2025)
Revenue falling to zero in 2025 is a structural red flag for long-term viability: it eliminates organic funding for operations, reduces ability to scale, and sharply increases reliance on external capital or partnerships to sustain R&D and commercial efforts over multiple quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A reported zero-debt position materially reduces solvency and interest-service risk over the medium term. That structural flexibility lets the company prioritize R&D and clinical timelines without mandatory fixed debt payments, improving survival odds through multi-year biotech cycles.
Read all positive factors
Neuroscientific Biopharmaceuticals Ltd. (NSB) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$32.92M
Dividend YieldN/A
Average Volume (3M)306.60K
Price to Earnings (P/E)―
Beta (1Y)1.10
Revenue GrowthN/A
EPS Growth-672.73%
CountryAU
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding332,575,700
10 Day Avg. Volume291,172
30 Day Avg. Volume306,603
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.76
Price to Sales (P/S)0.00
P/FCF Ratio-13.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Neuroscientific Biopharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
NeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. Its lead drug candidates include EmtinB for treatment of neurodegenerative...
Neuroscientific Biopharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
67
Positive
Cash Flow
18
Very Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 2.21M | 4.95M | 0.00 | 958.77K |
| Gross Profit | -92.78K | -91.34K | -57.85K | -64.92K | 897.36K |
| EBITDA | -1.92M | -1.80M | -5.96M | -10.37M | -3.12M |
| Net Income | -1.85M | 324.21K | -1.07M | -10.44M | -3.18M |
Balance Sheet | |||||
| Total Assets | 16.96M | 5.44M | 5.29M | 7.74M | 14.83M |
| Cash, Cash Equivalents and Short-Term Investments | 7.27M | 4.95M | 4.91M | 7.22M | 14.16M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 149.22K | 85.68K | 597.36K | 2.22M | 223.41K |
| Stockholders Equity | 16.81M | 5.35M | 4.69M | 5.52M | 14.60M |
Cash Flow | |||||
| Free Cash Flow | -941.33K | 42.43K | -2.30M | -6.95M | -2.63M |
| Operating Cash Flow | -941.33K | 44.25K | -2.30M | -6.94M | -2.60M |
| Investing Cash Flow | -36.04K | -1.81K | 0.00 | -3.87K | -29.88K |
| Financing Cash Flow | 3.29M | 0.00 | 0.00 | 0.00 | 13.51M |
Neuroscientific Biopharmaceuticals Ltd. Technical Analysis
Neutral
0.10
Price Trends
0.11
Negative
0.11
Negative
0.14
Negative
Market Momentum
>-0.01
Negative
52.90
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NSB, the sentiment is Neutral. The current price of 0.1 is above the 20-day moving average (MA) of 0.09, below the 50-day MA of 0.11, and below the 200-day MA of 0.14, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.90 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:NSB.
Neuroscientific Biopharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$67.67M | -7.57 | -179.37% | ― | ― | 16.61% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$212.57M | 27.58 | -15.96% | ― | -40.74% | -21.21% | |
46 Neutral | AU$32.92M | -5.38 | -19.10% | ― | ― | -672.73% | |
43 Neutral | AU$109.37M | -5.66 | -100.58% | ― | ― | 26.38% | |
42 Neutral | AU$58.88M | -5.28 | -62.49% | ― | ― | 10.78% | |
40 Underperform | AU$35.68M | -10.60 | -142.30% | ― | 110.44% | 35.90% |
* Healthcare Sector Average
AU:NSB
Neuroscientific Biopharmaceuticals Ltd.
0.10
0.07
230.00%
AU:CYP
Cynata Therapeutics Limited
0.29
0.09
50.00%
AU:PTX
Prescient Therapeutics Limited
0.06
0.02
43.59%
AU:SPL
Starpharma Holdings Limited
0.51
0.41
426.04%
AU:ILA
Island Pharmaceuticals Ltd
0.37
0.22
146.67%
AU:ADO
AnteoTech Ltd
0.01
<0.01
20.00%
Neuroscientific Biopharmaceuticals Ltd. Corporate Events
NeuroScientific scales up StemSmart manufacturing with Q-Gen for Phase 2 trials
Mar 16, 2026
NeuroScientific Biopharmaceuticals has started the first technology transfer manufacturing run for its StemSmart mesenchymal stem cell therapy at Q-Gen Cell Therapeutics in Brisbane. The move shifts StemSmart’s patented manufacturing process...
NeuroScientific Revenue Surges but Half-Year Loss Deepens and Asset Base Shrinks
Feb 25, 2026
NeuroScientific Biopharmaceuticals Limited reported its Appendix 4D results for the half-year ended 31 December 2025, highlighting a 359% increase in revenue from ordinary activities to $436,301 compared with the prior corresponding period. Despit...
NeuroScientific Advances StemSmart™ Program as Crohn’s Trial Prep Gathers Pace
Jan 29, 2026
NeuroScientific Biopharmaceuticals has advanced clinical and operational development of its StemSmart™ mesenchymal stem cell platform during the December 2025 quarter, with a particular focus on treating patients with severe, treatment-resis...
NeuroScientific’s StemSmart Therapy Delivers Strong Results in Fistulising Crohn’s Patients
Jan 12, 2026
NeuroScientific Biopharmaceuticals reported that three of four patients with fistulising Crohn’s disease treated with its patented StemSmart™ mesenchymal stem cell therapy under Australia’s Special Access Scheme achieved a succes...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.